RU2015100212A - Химерные белки на основе hpv/cyaa и их применение в индукции имунного ответа против hpv-инфекции и расстройств, вызываемых hpv - Google Patents
Химерные белки на основе hpv/cyaa и их применение в индукции имунного ответа против hpv-инфекции и расстройств, вызываемых hpv Download PDFInfo
- Publication number
- RU2015100212A RU2015100212A RU2015100212A RU2015100212A RU2015100212A RU 2015100212 A RU2015100212 A RU 2015100212A RU 2015100212 A RU2015100212 A RU 2015100212A RU 2015100212 A RU2015100212 A RU 2015100212A RU 2015100212 A RU2015100212 A RU 2015100212A
- Authority
- RU
- Russia
- Prior art keywords
- hpv
- protein
- type
- seq
- terminus
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title claims abstract 36
- 108020001507 fusion proteins Proteins 0.000 title claims abstract 36
- 230000028993 immune response Effects 0.000 title claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 7
- 208000009608 Papillomavirus Infections Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 230000006698 induction Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 claims abstract 65
- 108090000623 proteins and genes Proteins 0.000 claims abstract 65
- 229920001184 polypeptide Polymers 0.000 claims abstract 43
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 43
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 43
- 239000012634 fragment Substances 0.000 claims abstract 36
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract 22
- 239000000427 antigen Substances 0.000 claims abstract 22
- 102000036639 antigens Human genes 0.000 claims abstract 22
- 108091007433 antigens Proteins 0.000 claims abstract 22
- 210000004899 c-terminal region Anatomy 0.000 claims abstract 21
- 241000588832 Bordetella pertussis Species 0.000 claims abstract 4
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 claims 77
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 claims 77
- 230000001575 pathological effect Effects 0.000 claims 18
- 230000002265 prevention Effects 0.000 claims 14
- 230000004936 stimulating effect Effects 0.000 claims 12
- 238000011282 treatment Methods 0.000 claims 12
- 241000341655 Human papillomavirus type 16 Species 0.000 claims 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 230000001024 immunotherapeutic effect Effects 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 6
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 6
- 231100000590 oncogenic Toxicity 0.000 claims 6
- 230000002246 oncogenic effect Effects 0.000 claims 6
- 244000052769 pathogen Species 0.000 claims 6
- 230000001717 pathogenic effect Effects 0.000 claims 6
- 101710132595 Protein E7 Proteins 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 238000011321 prophylaxis Methods 0.000 claims 3
- 230000004044 response Effects 0.000 claims 2
- 241000588807 Bordetella Species 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 101100006983 Streptococcus mutans serotype c (strain ATCC 700610 / UA159) coaC gene Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y406/00—Phosphorus-oxygen lyases (4.6)
- C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
- C12Y406/01001—Aodenylate cyclase (4.6.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305898.4 | 2012-07-23 | ||
| EP12305898.4A EP2689786A1 (en) | 2012-07-23 | 2012-07-23 | HPV/CYAA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders |
| PCT/EP2013/065549 WO2014016312A1 (en) | 2012-07-23 | 2013-07-23 | Hpv/cyaa-based chimeric proteins and their uses in the induction of immune responses against hpv infection and hpv-induced disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015100212A true RU2015100212A (ru) | 2016-09-10 |
Family
ID=48832935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015100212A RU2015100212A (ru) | 2012-07-23 | 2013-07-23 | Химерные белки на основе hpv/cyaa и их применение в индукции имунного ответа против hpv-инфекции и расстройств, вызываемых hpv |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9827302B2 (enExample) |
| EP (2) | EP2689786A1 (enExample) |
| JP (1) | JP6466328B2 (enExample) |
| KR (1) | KR20150031487A (enExample) |
| CN (1) | CN104736173B (enExample) |
| AU (1) | AU2013295047B2 (enExample) |
| CA (1) | CA2879999A1 (enExample) |
| DK (1) | DK2874657T3 (enExample) |
| ES (1) | ES2712647T3 (enExample) |
| HR (1) | HRP20190108T1 (enExample) |
| HU (1) | HUE042808T2 (enExample) |
| LT (1) | LT2874657T (enExample) |
| MX (1) | MX2015001021A (enExample) |
| PL (1) | PL2874657T3 (enExample) |
| PT (1) | PT2874657T (enExample) |
| RS (1) | RS58313B1 (enExample) |
| RU (1) | RU2015100212A (enExample) |
| SI (1) | SI2874657T1 (enExample) |
| SM (1) | SMT201900057T1 (enExample) |
| TR (1) | TR201900695T4 (enExample) |
| WO (1) | WO2014016312A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2690172A1 (en) * | 2012-07-23 | 2014-01-29 | Genticel | CYAA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses |
| EP3037103A1 (en) * | 2014-12-23 | 2016-06-29 | Genticel | Immunotherapeutic vaccine comprising E7 proteins of HPV16 and HPV18 fused with CyaA, for use in subjects infected with HPV |
| EP3323424A1 (en) * | 2016-11-17 | 2018-05-23 | Cyanimal IP | Cyaa polypeptides as immune enhancer |
| CA3109889A1 (en) * | 2018-08-23 | 2020-02-27 | Glaxosmithkline Biologicals Sa | Immunogenic proteins and compositions |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01209817A (ja) | 1988-02-17 | 1989-08-23 | Yamaha Corp | 浮動少数点形ディジタル・アナログ変換器 |
| PT1188446E (pt) | 2000-09-15 | 2009-11-10 | Pasteur Institut | Vectores proteinácios para a distribuição da molécula a células que expressam cd11b |
| EP1489092A1 (en) | 2003-06-18 | 2004-12-22 | Institut Pasteur | Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof |
| PL1576967T3 (pl) * | 2004-03-18 | 2008-03-31 | Pasteur Institut | Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne |
| US8183007B2 (en) | 2008-07-22 | 2012-05-22 | Promega Corporation | ADP detection based methods using adenylate cyclase and bioluminescence |
| EP2478915A1 (en) * | 2011-01-24 | 2012-07-25 | Genticel | CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses |
-
2012
- 2012-07-23 EP EP12305898.4A patent/EP2689786A1/en not_active Withdrawn
-
2013
- 2013-07-23 EP EP13739725.3A patent/EP2874657B1/en active Active
- 2013-07-23 TR TR2019/00695T patent/TR201900695T4/en unknown
- 2013-07-23 DK DK13739725.3T patent/DK2874657T3/en active
- 2013-07-23 ES ES13739725T patent/ES2712647T3/es active Active
- 2013-07-23 CN CN201380049453.7A patent/CN104736173B/zh not_active Expired - Fee Related
- 2013-07-23 KR KR20157004540A patent/KR20150031487A/ko not_active Withdrawn
- 2013-07-23 PT PT13739725T patent/PT2874657T/pt unknown
- 2013-07-23 WO PCT/EP2013/065549 patent/WO2014016312A1/en not_active Ceased
- 2013-07-23 SI SI201331327T patent/SI2874657T1/sl unknown
- 2013-07-23 SM SM20190057T patent/SMT201900057T1/it unknown
- 2013-07-23 RU RU2015100212A patent/RU2015100212A/ru not_active Application Discontinuation
- 2013-07-23 LT LTEP13739725.3T patent/LT2874657T/lt unknown
- 2013-07-23 AU AU2013295047A patent/AU2013295047B2/en not_active Ceased
- 2013-07-23 JP JP2015523536A patent/JP6466328B2/ja not_active Expired - Fee Related
- 2013-07-23 MX MX2015001021A patent/MX2015001021A/es unknown
- 2013-07-23 US US14/416,384 patent/US9827302B2/en not_active Expired - Fee Related
- 2013-07-23 PL PL13739725T patent/PL2874657T3/pl unknown
- 2013-07-23 CA CA2879999A patent/CA2879999A1/en not_active Abandoned
- 2013-07-23 RS RS20190082A patent/RS58313B1/sr unknown
- 2013-07-23 HU HUE13739725A patent/HUE042808T2/hu unknown
- 2013-07-23 HR HRP20190108TT patent/HRP20190108T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2874657B1 (en) | 2018-10-17 |
| CA2879999A1 (en) | 2014-01-30 |
| JP2015524420A (ja) | 2015-08-24 |
| EP2689786A1 (en) | 2014-01-29 |
| JP6466328B2 (ja) | 2019-02-13 |
| CN104736173B (zh) | 2019-02-05 |
| EP2874657A1 (en) | 2015-05-27 |
| PL2874657T3 (pl) | 2019-05-31 |
| PT2874657T (pt) | 2019-02-18 |
| ES2712647T3 (es) | 2019-05-14 |
| DK2874657T3 (en) | 2019-02-11 |
| TR201900695T4 (en) | 2019-03-21 |
| US9827302B2 (en) | 2017-11-28 |
| KR20150031487A (ko) | 2015-03-24 |
| SI2874657T1 (sl) | 2019-03-29 |
| RS58313B1 (sr) | 2019-03-29 |
| LT2874657T (lt) | 2019-02-25 |
| HUE042808T2 (hu) | 2019-07-29 |
| HK1208822A1 (en) | 2016-03-18 |
| CN104736173A (zh) | 2015-06-24 |
| SMT201900057T1 (it) | 2019-02-28 |
| US20150250867A1 (en) | 2015-09-10 |
| MX2015001021A (es) | 2015-08-05 |
| HRP20190108T1 (hr) | 2019-03-22 |
| WO2014016312A1 (en) | 2014-01-30 |
| AU2013295047A1 (en) | 2015-02-05 |
| AU2013295047B2 (en) | 2018-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI490231B (zh) | 可用作誘發抗原專一性ｔ細胞反應之免疫原性增強劑之融合蛋白 | |
| US11185580B2 (en) | Compositions, methods and uses for improved human papilloma virus constructs | |
| AU2009265095B2 (en) | Vaccine composition useful for HPV and Hepatitis B infections and a method for preparing the same | |
| EA201790976A1 (ru) | Терапевтические вакцины против hpv16 | |
| Tyler et al. | Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing | |
| JP2010166921A5 (enExample) | ||
| Kawana et al. | Human papillomavirus vaccines: current issues & future | |
| RU2013102035A (ru) | Полипептиды е2 папилломавируса, применяемые для вакцинации | |
| TWI621627B (zh) | 用於豬生殖與呼吸綜合症及豬環狀病毒關聯疾病之疫苗組成物 | |
| RU2018142386A (ru) | Улучшение иммуногенности пептида l2 впч | |
| CN101481408A (zh) | 防止高度聚合的重组人乳头瘤病毒l1蛋白的修饰序列 | |
| CN103342738A (zh) | 人乳头瘤病毒e6蛋白可诱发同源蛋白间交叉反应性抗体的精细表位肽 | |
| CN103864936B (zh) | Hpv18型l2ne7e6融合蛋白基因、表达载体、方法、菌株和用途 | |
| JP2015524420A5 (enExample) | ||
| RU2015100211A (ru) | Химерные белки на основе cyaa, включающие гетерологичный полипептид, и их применение в индукции имунного ответа | |
| TR201900695T4 (en) | HPV / CYAA-BASED CHEMICAL PROTEINS AND THEIR USE IN INDUCING IMMUNE RESPONSE AGAINST HPV INFECTION AND HPV-INDUCED DISASTER. | |
| CN105753980B (zh) | 一种hpv18 e6单克隆抗体及其制备方法和应用 | |
| CN101885778B (zh) | Hpv16型l2n120e7e6融合蛋白、基因、制备方法及用途 | |
| CA2805300A1 (en) | Human papillomavirus e7 antigen compositions and uses thereof | |
| JP2013540421A5 (enExample) | ||
| US10329328B2 (en) | HPV-related fusion protein and applications thereof | |
| Li et al. | Protein transduction domain can enhance the humoral immunity and cross‑protection of HPV16L2 peptide vaccines | |
| JP2017526366A5 (enExample) | ||
| CN105646677A (zh) | 人乳头瘤病毒58e7蛋白表达纯化方法及应用 | |
| Rostami et al. | Expression of the Recombinant Hsp20-Nef Protein for Evaluation of its Immunogenicity against HIV-1 Nef using Indirect ELISA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20200526 |